Login / Signup

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.

Mathew VithayathilAntonio D'AlessioClaudia A M FulgenziNaoshi NishidaMartin SchönleinJohann von FeldenKornelius SchulzeHenning WegeAnwaar SaeedBrooke WietharnHannah HildebrandLinda WuCelina AngThomas U MarronArndt WeinmannPeter R GalleDominic BettingerBertram BengschArndt VogelLorenz BalcarBernhard ScheinerPei-Chang LeeYi-Hsiang HuangSuneetha AmaraMahvish MuzaffarAbdul Rafeh NaqashAntonella CammarotaNicola PersoneniTiziana PressianiMatthias PinterAlessio CortelliniMasatoshi KudoLorenza RimassaDavid J PinatoRohini Sharma
Published in: Liver international : official journal of the International Association for the Study of the Liver (2022)
Atezolizumab and bevacizumab therapy is associated with comparable efficacy and tolerability in older age patients with unresectable HCC.
Keyphrases
  • community dwelling
  • middle aged
  • physical activity
  • metastatic colorectal cancer
  • open label
  • locally advanced
  • stem cells
  • squamous cell carcinoma
  • liver metastases
  • bone marrow
  • cell therapy
  • rectal cancer